Phase 2 small-fibre neuropathy trials
- Reported quantity
- 4 mg subcutaneously
- Frequency
- Once daily
- Study duration
- 28 days in the placebo-controlled arms
Corneal nerve fibre density and pain scores were the reported endpoints.
Protocols · Regenerative
ARA-290: literature-reported ranges
ARA-290 is a non-erythropoietic fragment of EPO that targets the innate repair receptor. It has completed placebo-controlled human trials in sarcoidosis-associated small-fibre neuropathy, giving it a properly documented human figure.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- 11-amino-acid erythropoietin helix-B fragment
- Reported half-life
- Approximately 2 minutes in plasma
- Routes used in the literature
- Subcutaneous and intravenous in registered trials
- Also written as
- Cibinetide
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Diabetic and metabolic research arms
- Reported quantity
- 2–4 mg
- Frequency
- Once daily
- Study duration
- 28 days
The extremely short plasma half-life contrasts with effects reported over weeks.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
ARA-290 · 16 mg Vial
Ara-290 is dosed at 2 mg–4 mg daily via subcutaneous injection in educational protocols. A 16 mg vial reconstituted with bacteriostatic water yields about 8 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 2.0 mL bacteriostatic water → 8 mg/mL concentration.
- Target dose
- 4 mg once daily subcutaneously (after initial 2 mg titration).
- Easy measuring
- At 8 mg/mL, 1 unit = 0.01 mL = 80 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days.
Standard / Gradual Approach (2.0 mL = 8 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 2 mg (2,000 mcg) | 25 units (0.25 mL) |
| Weeks 2–8 (or up to 16) | 4 mg (4,000 mcg) | 50 units (0.50 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size ARA-290 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
ARA-290 · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit | 4 mg = |
|---|---|---|---|
| 10 mg | 3.33 mg/ml | 33 mcg | 120 units |
Unit columns use the range reported for this compound (4 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 10 mg vial in 2.5 mL of bacteriostatic water gives 4 mg/mL, so 1 mL draws the 4 mg trial figure.
Open the reconstitution calculatorHow to read these figures
- It is deliberately non-erythropoietic — it does not raise haematocrit like EPO.
- A 2-minute half-life with 28-day endpoints means the receptor interaction, not exposure time, is the proposed mechanism.
- Trial populations were specific neuropathy cohorts, not general.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study
Heij LR, Niesters M, Swartjes M, Hoitsma E, et al. · Mol Med · 2012 · DOI 10.2119/molmed.2012.00332
Sarcoidosis patients with small fiber neuropathy received subcutaneous ARA 290 (cibinetide) daily for 28 days in a randomized, double-blind pilot trial assessing safety and symptom efficacy.
View the record - [2]ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
Dahan A, Dunne A, Swartjes M, Proto P, et al. · Mol Med · 2013 · DOI 10.2119/molmed.2013.00122
Follow-up dosing study of subcutaneous ARA 290 (cibinetide) in sarcoidosis patients, reporting improvements in corneal nerve fiber density after a defined daily injection regimen.
View the record - [3]A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Araim Pharmaceuticals · ClinicalTrials.gov (NCT02039687) · 2015 · NCT02039687
Phase 2 dose-ranging trial testing multiple daily subcutaneous dose levels of ARA 290 in sarcoidosis patients over a 28-day treatment period.
View the record
Search the databases yourself
Read the ARA-290 research briefOther regenerative compounds
BPC-157Synthetic pentadecapeptide (gastric origin)BPC-157 + TB-500Pentadecapeptide + actin-sequestering fragment blendGHK-CuCopper-binding tripeptideGLOW BlendBlend — GHK-Cu, BPC-157 and TB-500
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.